Neha Mehta-Shah, MD, MSCI, of the Washington University School of Medicine in St. Louis, and Chadi Nabhan, MD, MBA, FACP, discuss the SWOG S1826 data presented by Alex Herrera, MD, of the City of Hope, during the 2023 American Society of Clinical Oncology Annual Meeting.
The randomized study compared nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) with brentuximab vedotin plus AVD in patients with advanced stage classic Hodgkin lymphoma.
“The study accrued 1,000 patients, kids and adults,” Dr. Mehta-Shah said. “It was the largest Hodgkin lymphoma study and was done in record time.”
The phase III trial showed that nivolumab plus AVD improved progression-free survival (PFS) over brentuximab vedotin plus AVD.
The one-year PFS rate was 94% in patients who received nivolumab plus AVD, significantly higher than the one-year PFS rate of 86% in those who recieved brentuximab vedotin plus AVD with a median follow-up of 12.1 months (hazard ratio, 0.48; 99% CI 0.27-0.87, one-sided P=.0005).